• Vaccine Name: Brucella abortus Omp3b/BCSP31/SOD recombinant attenuated Salmonella vector vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009432
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Goat
• Host Species as Laboratory Animal Model: Capra hircus
• Antigen: Omp3b; BCSP31; SOD
• Preparation: A mixture of three Brucella vaccine strains using a Salmonella-based delivery system, each expressing one of the recombinant B. abortus proteins Omp3b, BCSP31, or SOD, administered at 3.0 × 10^9 CFU/mL. (Kim et al, 2019a)
• Description: This study aimed to assess the protective efficacy of a novel Brucella vaccine formulation in goats using a Salmonella-based delivery system expressing recombinant Brucella abortus Omp3b, BCSP31, and SOD proteins. Efficacy: 40% of vaccinated animals were protected against B. abortus infection. The infection index and colonization of B. abortus in tested tissues were significantly lower in vaccinated goats compared to controls. Immune response: Vaccinated goats showed significantly higher serum immunoglobulin G titers and interferon gamma concentrations compared to controls, indicating significant antigen-specific immune responses. (Kim et al, 2019a)

Goat Response

• Immune Response: Vaccinated goats showed significantly higher serum immunoglobulin G titers and interferon gamma concentrations compared to controls, indicating significant antigen-specific immune responses. (Kim et al, 2019a)
• Challenge Protocol: Protection was evaluated by intraconjunctival challenge with virulent B. abortus strain 544 and subsequent assessment of infection index and bacterial colonization in tissues. (Kim et al, 2019a)
• Efficacy: 40% of vaccinated animals were protected against B. abortus infection. The infection index and colonization of B. abortus in tested tissues were significantly lower in vaccinated goats compared to controls. (Kim et al, 2019a)
• Description: Twenty Korean black goats were divided into two groups; group B was immunized with the vaccine mixture, and group A received the Salmonella vector only. Immune responses were measured by serum IgG titers and interferon gamma concentrations. Protection was evaluated by intraconjunctival challenge with virulent B. abortus strain 544 and subsequent assessment of infection index and bacterial colonization in tissues. (Kim et al, 2019a)